SCHEMBL24313655

SCHEMBL24313655

CC(C)c1ccc2cc(C(=O)NS(=O)(=O)c3ccccc3)oc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT1 P54687 4/20 0.53
ALDH1A1 P00352 2/20 0.48
LMNA P02545 2/20 0.48
THRB P10828 1/20 0.48
KAT6A Q92794 1/20 0.46
MMP13 P45452 3/20 0.45
MMP2 P08253 3/20 0.45
ADAMTS4 O75173 1/20 0.45
MMP7 P09237 1/20 0.45
MMP12 P39900 1/20 0.45
MMP14 P50281 1/20 0.45
GAA P10253 3/20 0.45
MAPK1 P28482 1/20 0.45
PTGER4 P35408 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31723078 0.85 ALDH1A1 (0.43) BCAT1ALDH1A1LMNATHRBMMP13
SCHEMBL22588237 0.81 BCAT1 (0.53) BCAT1ALDH1A1LMNAGAAPTGER4
SCHEMBL24314244 0.80 GAA (0.46) ALDH1A1LMNATHRBGAAMAPK1
SCHEMBL22587711 0.79 BCAT1 (0.51) BCAT1ALDH1A1LMNAMMP2MMP14
SCHEMBL22588370 0.77 BCAT1 (0.49) BCAT1ALDH1A1LMNAMMP2MMP14
SCHEMBL24313815 0.76 TAS1R3 (0.42) ALDH1A1LMNATHRBMMP2PTGER4
SCHEMBL31723093 0.76 TAS1R3 (0.42) ALDH1A1LMNATHRBMMP2PTGER4
SCHEMBL24313896 0.76 PIM1 (0.50) ALDH1A1LMNATHRBGAANPC1
SCHEMBL24313971 0.76 ALDH1A1 (0.41) BCAT1ALDH1A1LMNATHRBMMP13
SCHEMBL31723097 0.76 ALDH1A1 (0.41) BCAT1ALDH1A1LMNATHRBMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081842-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed